Kezar Life Sciences Inc
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyo… Read more
Kezar Life Sciences Inc (KZR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.118x
Based on the latest financial reports, Kezar Life Sciences Inc (KZR) has a cash flow conversion efficiency ratio of -0.118x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.83 Million) by net assets ($82.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kezar Life Sciences Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Kezar Life Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Kezar Life Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kezar Life Sciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CastleNet Technology
TWO:8059
|
-0.066x |
|
H&R GmbH & Co. KGaA
XETRA:2HRA
|
0.054x |
|
Lument Finance Trust Inc
NYSE:LFT
|
0.005x |
|
KLEA HOLDING
PA:ALKLH
|
0.033x |
|
TECH.OLYMPIC NA EO 5
F:TQZA
|
N/A |
|
Commercial National Financial Corporation
PINK:CEFC
|
N/A |
|
Zuari Agro Chemicals Limited
NSE:ZUARI
|
0.202x |
|
Bound and Beyond PCL
BK:BEYOND
|
0.068x |
Annual Cash Flow Conversion Efficiency for Kezar Life Sciences Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Kezar Life Sciences Inc from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $116.92 Million | $-74.21 Million | -0.635x | -45.83% |
| 2023-12-31 | $187.57 Million | $-81.64 Million | -0.435x | -99.62% |
| 2022-12-31 | $269.87 Million | $-58.85 Million | -0.218x | -1.16% |
| 2021-12-31 | $196.88 Million | $-42.44 Million | -0.216x | +17.76% |
| 2020-12-31 | $140.98 Million | $-36.95 Million | -0.262x | +31.54% |
| 2019-12-31 | $78.05 Million | $-29.88 Million | -0.383x | -100.31% |
| 2018-12-31 | $108.80 Million | $-20.79 Million | -0.191x | -160.54% |
| 2017-12-31 | $-25.69 Million | $-8.11 Million | 0.316x | -43.63% |
| 2016-12-31 | $-17.43 Million | $-9.76 Million | 0.560x | -- |